Gwen A. Fyfe
Direttore/Membro del Consiglio presso Molecular Partners, Inc.
Posizioni attive di Gwen A. Fyfe
Società | Posizione | Inizio | Fine |
---|---|---|---|
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Gwen A. Fyfe
Precedenti posizioni note di Gwen A. Fyfe
Società | Posizione | Inizio | Fine |
---|---|---|---|
MOLECULAR PARTNERS AG | Direttore/Membro del Consiglio | 11/05/2017 | 21/04/2021 |
ARRAY TECHNOLOGIES, INC. | Direttore/Membro del Consiglio | 26/01/2012 | 30/07/2019 |
Independent Dir/Board Member | 26/01/2012 | 30/07/2019 | |
CASCADIAN THERAPEUTICS INC (USA) | Direttore/Membro del Consiglio | 09/01/2016 | 09/03/2018 |
INFINITY PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 12/03/2012 | 17/06/2016 |
Independent Dir/Board Member | 12/03/2012 | 17/06/2016 | |
PHARMACYCLICS, INC. | Direttore/Membro del Consiglio | 09/11/2010 | 30/06/2011 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/1997 | 01/01/2009 |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Direttore/Membro del Consiglio | 17/12/2013 | - |
Independent Dir/Board Member | 17/12/2013 | - |
Formazione di Gwen A. Fyfe
Washington University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Svizzera | 2 |
Posizioni
Director/Board Member | 7 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 1 |
Settori
Health Technology | 9 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
INFINITY PHARMACEUTICALS, INC. | Health Technology |
MOLECULAR PARTNERS AG | Health Technology |
Aziende private | 6 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Health Technology |
- Borsa valori
- Insiders
- Gwen A. Fyfe
- Esperienza